Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Diltiazem ER on E2027 PK in Healthy Subjects
NCT02947711Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Irsenontrine in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with any adverse event (AE) and any serious adverse event (SAE), Mean values for hematology and blood chemistry parameters at Day 27 and 6 more. Started Oct 2016; status: completed.
02
Drugs
Irsenontrine
03
Conditions
dementia with Lewy bodies (DLB)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02947711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947711.